Nanometics

Nanometics is a biotechnology company specializing in the development of mitochondria-targeted nanoparticle therapeutics for a range of high-need indications. The company utilizes a proprietary platform of biodegradable polymeric nanoparticles, such as PLGA-PEG, which are functionalized to specifically penetrate the mitochondrial membrane and deliver therapeutic payloads. This approach is designed to enhance the efficacy of drugs in treating conditions like drug-resistant cancers, atherosclerosis, and neurodegenerative diseases while minimizing off-target toxicity. Founded as a spin-off from academic research, Nanometics has advanced several preclinical programs, including mitochondria-targeted platinum agents and antioxidants. The company's strategy focuses on leveraging organelle-specific delivery to address the underlying mitochondrial dysfunction associated with chronic and metabolic diseases.